Genomma Lab achieves 17.4% Top Line Growth and a 14.8% EBITDA Growth in First Quarter of 2013

GENOMMA LAB INTERNACIONAL ANNOUNCES ITS FIRST QUARTER 2013 RESULTS

Mexico City, Mexico –April 25th, 2013

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB.B) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended March 31, 2013. All figures included herein are stated in nominal Mexican pesos and were prepared in accordance with International Financial Reporting Standards (IFRS). As of January 1st of 2012, the Company adopted IFRS as the accounting framework for its financial statements to comply with the provisions established by the Mexican National Banking and Securities Commission (CNBV).

1Q 2013 Highlights (vs. 1Q 2012)

- Net Sales for the quarter reached Ps. 2.08 billion, increasing 17.4%, compared to the same period of 2012.
- Sales from our international operations increased 142.4% in the first quarter to Ps. 1.03 billion, compared to the same quarter of 2012.
- EBITDA increased 14.8% in the first quarter to Ps. 329.7 million, representing a 15.8% margin.
- Consolidated Net Income increased 4.5% to Ps. 147.9 million in the first quarter, compared to the same quarter of 2012. Earnings per Share[1] increased 12.2% to Ps. 1.49, compared to the same period of 2012.
- Days of Clients improved 22 days from 176 days as of December 31, 2012 to 154 days as of March 31, 2013.
- The initiatives in our international operations, especially the one in the United States with Walgreens and Wal-Mart, are continuing to show positive results.
- During the first quarter, Genomma Lab successfully launched 8 products under 3 existing brands and 21 products under 2 new brands.

[1] Earnings per Share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

Contact:
Investor Relations
Tel: +52 (55) 5081-0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, mentioned: "In this first quarter of 2013 the Company showed results that were in line with our full-year guidance. Growth was driven by our international operations, mainly Brazil, the United States, Argentina and Colombia, and we had very strong results in the rest of Latin America.

We are seeing positive results for the initiatives implemented during previous quarters in our international operations. The initiative we have in the United States with Walgreens and Wal-Mart continues to expand, increasing our presence among the Hispanic market of this country while posting positive results for the Company. We are optimistic about the results expected for the rest of the year. In Argentina, we closed the acquisition for the brand *Tafirol* in January of this year, strengthening Genomma Lab's position as the number one player in the OTC market in this country, according to IMS Health. We will continue to focus on improving the positioning of this brand and the brands acquired last year in this country.

In Mexico, we continue to work on strengthening our position in the market, which has implied making strong strategic decisions. The implementation of stricter commercial policies with our clients is starting to show signs of improvement in our cash conversion cycle, and we expect further benefits in the coming quarters. This policy implementation, added to a weak consumption in Mexico, had a negative effect on the sales during this period; however, since the first quarter is the weakest of the year in terms of seasonality, the effect of this period will not affect our expected full-year results. We expect to see considerably better results during the following quarters for our Mexican operations.

We are optimistic about the rest of the year. We expect to see a stronger effect of our different initiatives during the second half of the year that will lead us to meet our full-year guidance, which is to grow between 19% and 20% in Net Sales with an EBITDA margin of at least 26.5%."

Consolidated Results of Operations for the First Quarter of 2013

The following table shows consolidated results of operations, in millions of pesos (except share and per-share data), and margins are shown as a percentage of Net Sales. All figures of 2013 are compared to the same period of the previous year:

For the quarter ended March 31, 2013 and 2012
(In millions of current Mexican Pesos)

	1st Quarter		
	2013	2012	%Var
Net Sales	2,084.2	1,775.4	17.4
Gross Profit	1,436.8	1,235.4	16.3
Gross Margin	68.9%	69.6%	(0.7)
EBITDA[1]	329.7	287.3	14.8
EBITDA Margin	15.8%	16.2%	(0.4)
Operating Income	315.6	271.1	16.4
Operating Income Margin	15.1%	15.3%	(0.2)
Net Income of Majority Shareholders	131.3	134.7	(2.5)
Net Income of Majority Shareholders Margin	6.3%	7.6%	(1.3)
Weighted average number of shares outstanding	1,048,733,370	1,051,969,811	(0.3)
EPS (12 months)[2]	1.49	1.33	12.2

[1] EBITDA is calculated by adding depreciation and amortization to the Operating Income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of March 31, 2013 totaled 1,048,733,370.

Net Sales rose 17.4% to Ps. 2.08 billion in the first quarter of 2013, from Ps. 1.78 billion in the first quarter of 2012.

Net Sales by brands are classified as follows:

1) **Base Brands** represent brands launched at least two years prior to the last fiscal year (2011, 2010, 2009 and earlier) in Mexico;
2) **Prior Year Launches** are brands launched during the prior fiscal year (2012) in Mexico;
3) **New Brands** are brands launched during the current fiscal year (2013) in Mexico; and
4) **International** refers to Net Sales of our international operations.

The increase in Net Sales resulted from the combination of the following factors:

i) a 33.2% decrease (Ps. 446.0 million) from **Base Brands** in Mexico during the first quarter, amounting to Ps. 897.9 billion, including line extensions on these;

ii) an increase of Ps. 124.4 million from **Prior Year Launches** in Mexico during the first quarter due to the full year effect, including the recent line extensions on these brands, resulting in Ps. 130.7 million;

iii) Ps. 24.9 million in the first quarter of 2013 from **New Brands** in Mexico; and,

iv) a 142.4% increase (Ps. 605.6 million) from **international** operations, totaling Ps. 1.03 billion in the first quarter of 2013.

Gross Profit increased 16.3% to Ps. 1.44 billion in the first quarter of 2013, compared to Ps. 1.24 billion during the first quarter of 2012. Gross Margin decreased 0.7 percentage points, as a percentage of Net Sales, to 68.9% in the first quarter of 2013, compared to 69.6% in the same period of 2012. This decrease in margin was primarily due to a higher participation of our US operations, as a percentage of Net Sales, which have a higher cost of goods sold as a percentage of Net Sales.

Selling, General and Administrative Expenses, as a percentage of Net Sales, decreased 0.3 percentage points to 54.1% in the first quarter of 2013, compared to 54.4% in the same period of 2012. This decrease was mainly derived from economies of scale achieved by a more efficient management of our Selling, General and Administrative Expenses.

EBITDA increased 14.8% to Ps. 329.7 million in the first quarter of 2013, compared to Ps. 287.3 million in the first quarter of 2012. The EBITDA margin decreased 0.4 percentage points, as a percentage of Net Sales, to 15.8% in the first quarter of 2013, from 16.2% in the first quarter of 2012.The EBITDA margin decrease was primarily due to an increase in the cost of goods sold, as a percentage of Net Sales, which was offset by a decrease in the Selling, General and Administrative Expenses (excluding Depreciation and Amortization), as a percentage of Net Sales.

EBITDA Reconciliation

For the first quarter ended March 31, 2013 and 2012
(In millions of current Mexican pesos)

	First Quarter	
	2013	2012
Consolidated net income (loss)	147.9	141.6
Income tax expense (benefit)	68.2	62.1
Not consolidated subsidiaries (income)	(8.7)	4.3
Comprehensive financing (income) cost	108.2	63.2
Operation income	**315.6**	**271.1**
Depreciation and amortization	14.1	16.1
EBITDA	**329.7**	**287.3**
EBITDA margin	*15.8%*	*16.2%*

Operating Income increased 16.4% to Ps. 315.6 million in the first quarter of 2013, compared to Ps. 271.1 million in the first quarter of 2012. Operating Margin, as a percentage of Net Sales, decreased 0.2 percentage points, reaching 15.1% in the first quarter of 2013, from 15.3% in the same period of 2012.

Comprehensive Financing Result represented a Ps. 108.2 million loss in the first quarter of 2013, which represented an increase of Ps. 45.1 million in the loss, compared to a loss of Ps. 63.2 million recorded in the first quarter of 2012. This change was a result of: i) a Foreign Exchange loss amounting to Ps. 43.3 million during the first quarter of 2013, compared to a Ps. 49.0 million loss during the same period of 2012, resulting primarily from a depreciation of the US Dollar exchange rate vs. the Company's operating currencies, which was reflected on the Company's cash position in US Dollars; ii) an increase in Financial Expenses of Ps. 50.5 million to Ps. 74.0 million during the first quarter of 2013, compared to Ps. 23.5 million during the same period of 2012; iii) a lower Interest Income of Ps. 1.7 million during the first quarter of 2013, compared to Ps. 4.6 million in the same period of 2012; and, iv) a Ps. 7.3 million gain in the first quarter of 2013 related to the Exchange Rate conversions from foreign operations, compared to a Ps. 4.7 million gain in the same period of 2012.

Consolidated Net Income increased 4.5% to Ps. 147.9 million in the first quarter of 2013, representing a margin of 7.1% over Net Sales, compared to Ps. 141.6 million in the first quarter of 2012, which represented a margin of 8.0%.

Balance Sheet

As of March 31, 2013, March 31, 2012 and December 31, 2012
(In millions of current Mexican pesos)

	March 31, 2013	March 31, 2012	Var Mar '13 vs Mar '12	% Var Mar '13 vs Mar'12	December 31, 2012	Var Mar '13 vs Dec '12	% Var Mar'13 vs Dec '12
Balance Sheet Information:							
Cash and Equivalents	**1,020.9**	963.7	57.2	5.9%	917.2	103.7	11.3%
Clients	**4,320.2**	3,870.5	449.7	11.6%	4,795.6	(475.3)	-9.9%
Inventories	**1,078.2**	1,099.2	(21.0)	-1.9%	1,032.4	45.8	4.4%
Other current Assets	**1,742.7**	394.7	1,348.0	341.5%	1,470.5	272.2	18.5%
Total Assets	**13,127.9**	8,873.3	4,254.6	47.9%	12,992.6	135.3	1.0%
Suppliers	**1,038.5**	828.3	210.1	25.4%	1,218.7	(180.2)	-14.8%
Other current Liabilities	**931.9**	970.0	(38.0)	-3.9%	1,004.6	(72.7)	-7.2%
Current portion of long term debt	**1,225.4**	-	1,225.4	-	406.6	818.8	201.4%
Long-term Loans with financial institutions	**2,520.1**	1,320.0	1,200.1	90.9%	3,052.3	(532.2)	-17.4%
Total Liabilities	**6,008.7**	3,231.3	2,777.4	86.0%	5,973.8	34.9	0.6%
Stockholders Equity	**7,119.2**	5,642.0	1,477.2	26.2%	7,018.8	100.4	1.4%
Working Capital (1)	**6,191.6**	4,529.8	1,661.8	36.7%	5,992.4	199.2	3.3%
Working Capital less cash	**5,170.7**	3,566.1	1,604.6	45.0%	5,075.2	95.5	1.9%
Accounts Receivable days	**154**	167	(13)	-7.8%	176	(22)	-12.6%
Inventories days	**122**	154	(32)	-20.7%	121	1	1.2%
Suppliers days	**118**	116	2	1.3%	143	(25)	-17.5%
Cash Conversion Cycle	**158**	205	(47)	-22.7%	154	4	2.8%

(1) Working capital consists of current assets minus current liabilities.

Cash and Equivalents increased 5.9% (Ps. 57.2 million) to Ps. 1.02 billion as of March 31, 2013, compared to Ps. 963.7 billion as of March 31, 2012. This increase was mainly due to cash generated from our operations during the last twelve months, which was offset by several payments for brand acquisitions amounting to Ps. 1.79 billion that were financed with an increase in loans with financial institutions.

Clients amounted to Ps. 4.32 billion as of March 31, 2013, compared to Ps. 3.87 billion as of March 31, 2012. Days of Clients decreased 13 days to 154 days as of March 31, 2013, from 167 days as of March 31, 2012. This decrease in days is the result of our stricter commercial policies with clients, mainly in Mexico, which will continue to show signs of improvement going forward.

Inventories amounted to Ps. 1.08 billion as of March 31, 2013, compared to Ps. 1.10 billion as of March 31, 2012. Days of Inventories decreased 32 days to 122 days as of March 31, 2013, compared to 154 days as of March 31, 2012. This decrease was mainly due to the recent implementation of outsourced manufacturing of some of our products in countries outside of Mexico, as well as to a more efficient inventory management derived from our new Warehouse Management System.

Suppliers amounted to Ps. 1.04 billion as of March 31, 2013, compared to Ps. 828.3 million as of March 31, 2012. Days of Suppliers increased 2 days to 118 as of March 31, 2013, from 116 days as of March 31, 2012. Days of Suppliers in the first quarter of 2012 decreased importantly because of the Enterprise Resource Planning (ERP) System implementation, while in the same quarter of this year they remain low mainly because of the initiation of outsourced manufacturing outside of Mexico that implied shorter payment terms to our suppliers. We expect these terms to normalize as volume and scale increase.

Other Current Assets amounted to Ps. 1.74 billion as of March 31, 2013, from Ps. 394.7 million as of March 31, 2012. This increase was primarily derived from advertisement paid in advance, as well as from payments made in advance to suppliers, mainly to support growth in the international operations.

Other Current Liabilities amounted to Ps. 931.9 million as of March 31, 2013, from Ps. 970.0 million as of March 31, 2012.

Long-Term Loans with Financial Institutions amounted to Ps. 3.75 billion as of March 31, 2013, compared to Ps. 1.32 billion as of March 31, 2012. The current portion of long term debt amounted to Ps. 1.23 billion as of March 31, 2013. The Net Debt to EBITDA ratio as of March 31, 2013 was of 1.05. Currently, the Company has five banking facilities in Mexico with different relationship banks: a) a Ps. 1.30 billion amortizing long-term loan; b) a Ps. 700.0 million medium-term revolving line; and, c) three long-term bullet payment loans: one for Ps. 700.0 million, one for Ps. 600.0 million, and a third one for Ps. 850 million. Also, the Company has a medium-term simple loan in Argentina amounting to $60.0 million Argentinean pesos.

Cash Conversion Cycle reached 158 days at the end of the first quarter of 2013, compared to 205 days at the end of the same period of 2012. This strong improvement was mainly derived from the initiatives that are being implemented with our clients to reduce accounts receivable and from the decrease in inventory days given the ERP and WMS implementations.

Operations Summary

Net Sales Segmentation for the First Quarter of 2013

During the first quarter of 2013, OTC pharmaceutical products represented 57.6%[3] of our Mexican sales, personal care products represented 40.8%[4], and generic pharmaceutical products represented 1.7%[5].

Net Sales of our OTC pharmaceutical products in Mexico increased 5.9%[3] during the first quarter of 2013, compared to the first quarter of 2012.

Net Sales of our personal care products in Mexico amounted to Ps. 429.4[4] million in the first quarter of 2013. During the first quarter of 2013, the Company launched 29 new personal care products in Mexico.

Net Sales of our generic pharmaceutical products amounted to Ps. 17.5 million[5] in the first quarter of 2013. We will continue to work on consolidating this brand in the Mexican market.

Net Sales from our International Operations increased 142.4% to Ps. 1.03 billion for the first quarter of 2013, compared to Ps. 425.2 million for the same period in 2012.

(In millions of current Mexican Pesos)

	1Q13				1Q12				
	OTC	PC	BG	Total 1Q13	OTC	PC	BG	Total 1Q12	%Var
Mexico	606.5	429.4	17.5	**1,053.5**	572.7	737.0	40.5	**1,350.2**	-22.0%
International	201.9	828.8	-	**1,030.7**	34.9	390.2	-	**425.2**	142.4%
TOTAL	**808.4**	**1,258.3**	**17.5**	**2,084.2**	**607.6**	**1,127.3**	**40.5**	**1,775.4**	**17.4%**

*BG: Branded Generics

[3] Includes only OTC products in Mexico
[4] Includes only personal care products in Mexico
[5] This initiative is only for Mexico

New Product Launches and Line Extensions

During 2013, the Company has launched 8 line extensions from our **Base Brands** and **Prior Year Launches,** and 21 new products under **New Brands.** Some of the products recently launched are:

> *Zan Zusi,* our recently acquired brand, is a color cosmetics line of products for eyes and face. *Zan Zusi* has been reformulated and launched to the market with a new image that projects quality and elegance at an accessible price.
>
> *Nórdiko deodorants and antiperspirants*, a line extension of our *Nórdiko* brand, acquired in 2011 from Colgate-Palmolive, is a new line of personal care products for men that enters the market with several presentations of deodorants and antiperspirants.

Also, during 2013 we have successfully launched several products in our international operations, such as *Next,* our internally developed brand, in the United States. *Next*, the number 1 anti-flu OTC product in Mexico, is indicated for the relief of some of the symptoms caused by the flu.

Other Corporate Events

- The Company has recently made some organizational changes with the purpose of making its international operations more efficient:
  - Máximo Juda, currently responsible for the Argentinean and Brazilian operations, is assuming the International Vice-President position, replacing José Mariano de la Peña, who will be responsible for the Business Development area of the Company.
  - The International Vice-Presidency will report directly to the CEO, and will be responsible for all of the Company's international subsidiaries.

Analyst Coverage

Actinver Casa de Bolsa S.A. de C.V.; Banco Itaú BBA, S.A.; BBVA Bancomer, S.A. Institución de Banca Múltiple; BTG Pactual US Capital LLC; Casa de Bolsa Credit Suisse S.A.; GBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de Bolsa; Grupo Financiero Monex; HSBC Securities (USA) Inc.; Intercam Casa de Bolsa, S.A. de C.V.; Invex Grupo Financiero S.A. de C.V.; IXE Casa de Bolsa S.A. de C.V. Grupo Financiero Banorte; Santander Investment Securities Inc.; Signum Research; UBS Casa de Bolsa S.A. and Vector Casa de Bolsa.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three month period ended on March 31, 2013 and March 31, 2012

(In thousands of current Mexican pesos)

	FIRST QUARTER		VAR
	2013	2012	%
Net Sales	2,084,209	1,775,351	17.4%
Costs and Expenses	647,385	539,995	19.9%
Gross Income	**1,436,824**	**1,235,356**	**16.3%**
Selling, general and administrative expenses	1,113,209	948,810	17.3%
Other expenses	396	984	(59.8%)
Other income	6,504	1,725	277.0%
EBITDA	**329,723**	**287,287**	**14.8%**
Depreciation and amortization	14,093	16,140	(12.7%)
Income from Operations	**315,630**	**271,147**	**16.4%**
Interest expense	(74,008)	(23,482)	215.2%
Interest income	1,729	4,554	(62.0%)
Exchange income (expense)	(35,962)	(44,242)	(18.7%)
Comprehensive financing income (cost)	**(108,241)**	**(63,170)**	**71.3%**
Income (loss) of not consolidated subsidiaries	8,718	(4,309)	(302.3%)
Income before income taxes	**216,107**	**203,668**	**6.1%**
Income tax expense	68,202	62,083	9.9%
Consolidated Net Income	**147,905**	**141,585**	**4.5%**
Net income of minority stockholders	16,651	6,933	140.2%
Net (loss) of majority stockholders	**131,254**	**134,652**	**(2.5%)**
Conversion result from foreign currencies	(46,347)	(60,063)	(22.8%)
Comprehensive Income	**84,907**	**74,589**	**13.8%**

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of March 31, 2013, March 31, 2012 and December 31, 2012
(In thousands of current Mexican pesos)

	MARCH		DECEMBER	VARIATION			
ASSETS	**2013**	**2012**	**2012**	**MAR -12**	**%**	**DEC -12**	**%**
Current assets							
Cash and equivalents	1,013,247	934,480	884,416	78,767	8%	128,831	15%
Restricted Fund	7,651	29,219	32,750	(21,568)	(74%)	(25,099)	(77%)
Clients-Net	4,320,242	3,870,527	4,795,560	449,715	12%	(475,318)	(10%)
Other accounts receivable	386,746	154,258	275,653	232,488	151%	111,093	40%
Due from related parties	212,395	59,322	195,624	153,073	258%	16,771	9%
Inventory - net	1,078,154	1,099,157	1,032,400	(21,003)	(2%)	45,754	4%
Prepaid expenses	1,143,582	181,157	999,261	962,425	531%	144,321	14%
Total current assets	**8,162,017**	**6,328,120**	**8,215,664**	**1,833,897**	**29%**	**(53,647)**	**(1%)**
Non-current assets							
Trademarks	3,726,057	1,979,823	3,382,239	1,746,234	88%	343,818	10%
Investments in subsidiaries	13,925	1,545	5,680	12,380	801%	8,245	145%
Building, properties and equipment – Net	395,867	430,455	403,588	(34,588)	(8%)	(7,721)	(2%)
Deferred income tax	23,868	9,084	14,092	14,784	163%	9,776	69%
Other assets - net	806,147	124,303	971,327	681,844	549%	(165,180)	(17%)
Total non-current assets	**4,965,864**	**2,545,210**	**4,776,926**	**2,420,654**	**95%**	**188,938**	**4%**
Total assets	**13,127,881**	**8,873,330**	**12,992,590**	**4,254,551**	**48%**	**135,291**	**1%**
LIABILITIES AND STOCKHOLDERS' EQUITY							
Current Liabilities							
Current portion of long term loan w/ financial institutions	1,225,425	-	406,621	1,225,425	100%	818,804	201%
Trade accounts payable	1,038,471	828,342	1,218,663	210,129	25%	(180,192)	(15%)
Due to related parties	8,750	12,386	9,480	(3,636)	(29%)	(730)	(8%)
Other current liabilities	865,195	805,310	909,060	59,885	7%	(43,865)	(5%)
Income tax payable	53,077	143,976	82,966	(90,899)	(63%)	(29,889)	(36%)
Statutory employee profit sharing	4,920	8,280	3,110	(3,360)	(41%)	1,810	58%
Total current liabilities	**3,195,838**	**1,798,294**	**2,629,900**	**1,397,544**	**78%**	**565,938**	**22%**
Non-current liabilities							
Long-term loans with financial institutions	2,520,088	1,320,000	3,052,275	1,200,088	91%	(532,187)	(17%)
Trade accounts payable LT	60,562	110,793	60,562	(50,231)	(45%)	-	-
Deferred income tax	230,389	1,123	229,370	229,266	20415%	1,019	0%
Employee retirement obligations	1,814	1,117	1,659	697	62%	155	9%
Total liabilities	**6,008,691**	**3,231,327**	**5,973,766**	**2,777,364**	**86%**	**34,925**	**1%**
Stockholders' equity							
Capital stock	1,921,660	1,921,660	1,921,660	-	-	-	-
Retained earnings	5,156,955	3,631,837	3,592,019	1,525,118	42%	1,564,936	44%
Net income	131,254	134,652	1,564,936	(3,398)	(3%)	(1,433,682)	(92%)
Cumulative translation effects of foreing subsidiaries	(41,652)	5,566	4,695	(47,218)	(848%)	(46,347)	(987%)
Share buy back fund	(158,012)	(104,189)	(159,952)	(53,823)	52%	1,940	(1%)
Net premium in placement of repurchased shares	39,749	19,612	39,749	20,137	103%	-	-
Minority interest	69,236	32,865	55,717	36,371	111%	13,519	24%
Total stockholders' equity	**7,119,190**	**5,642,003**	**7,018,824**	**1,477,187**	**26%**	**100,366**	**1%**
Total equity and liabilities	**13,127,881**	**8,873,330**	**12,992,590**	**4,254,551**	**48%**	**135,291**	**1%**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three month period ended on March 31, 2013
(In thousands of current Mexican pesos)

	MARCH 2013 ACCUMULATED
Cash and cash equivalents beginning of period	**917,166**
Consolidated Net Income	**147,905**
Charges to results with no cash flow:	
Depreciation and amortization	14,093
Income tax	68,201
Others	53,723
	283,922
Changes in Working Capital:	
Clients-Net	475,201
Inventories	(45,754)
Suppliers	(180,146)
Other current assets	(260,013)
Payed income tax	(154,372)
Other current liabilities	44,356
	(120,728)
Net cash generated (used) in operating activities	**163,194**
Investing activities:	
Investment in fixed assets	(8,825)
Sales of equipment	8,523
Brand Acquisitions	(281,175)
Other assets acquisitions	(1,495)
Net cash generated (used) in investing activities	**(282,972)**
Financing activities:	
Payments of borrowings with financial institutions	-
Loans with financial institutions	300,000
Interest paid	(33,700)
Stock Repurchase	(518)
Stock sale	-
Minority Interest	(3,132)
Net cash used in financing activities	**262,650**
Net increase in cash and cash equivalents before foreign exchange adjustments coming from International operations and inflationary effects.	**142,872**
Foreign exchange and inflationary effects from International operations	(39,139)
Accumulated cash flow at the end of the period	**1,020,898**
Less- restricted fund	7,651
Cash and cash equivalents at end of period balance for operation	**1,013,247**